Table 2.
Underlying Conditions Reported Among Case Patients With Invasive Group A Streptococcus Disease by Surveillance Site, 2005–2012
| Underlying Conditionb | ABCs Site, No. (%)a | Total (n = 9232) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CA (n = 1043) | CO (n = 1075) | CT (n = 934) | GA (n = 1075) | MD (n = 1011) | MN (n = 1278) | NM (n = 975) | NY (n = 607) | OR (n = 434) | TNc (n = 800) | ||
| Diabetes mellitus | 215 (20.6)d | 237 (22.1)d | 258 (27.6)d | 262 (24.4) | 265 (26.2) | 306 (23.9) | 270 (27.7)d | 160 (26.4) | 94 (21.7) | 237 (29.6)d | 2304 (25.0) |
| Acute skin breakdowne | 211 (20.2) | 180 (16.7)d | 183 (19.6) | 255 (23.7)d | 264 (26.1)d | 243 (19.0) | 222 (22.8)d | 108 (17.8) | 127 (29.3)d | 55 (6.9)d | 1848 (20.0) |
| Heart diseasef | 155 (14.9)d | 145 (13.5)d | 223 (23.9)d | 217 (20.2) | 214 (21.2)d | 231 (18.1) | 166 (17.0) | 165 (27.2)d | 60 (13.8)d | 189 (23.6)d | 1765 (19.1) |
| Smoker | 231 (22.2)d | 163 (15.2) | 132 (14.1) | 157 (14.6) | 279 (27.6)d | 150 (11.7)d | 160 (16.4) | 65 (10.7)d | 93 (21.4)d | 126 (15.8) | 1556 (16.3) |
| Cancerg | 113 (10.8) | 93 (8.7) | 129 (13.8)d | 125 (11.6)d | 116 (11.5)d | 142 (11.1)d | 69 (7.1)d | 31 (5.1)d | 44 (10.1) | 69 (8.6) | 931 (10.1) |
| Alcohol use | 131 (12.6)d | 105 (9.8)d | 60 (6.4) | 65 (6.1)d | 75 (7.4) | 85 (6.7) | 134 (13.7)d | 42 (6.9) | 38 (8.8) | 41 (5.1)d | 776 (8.4) |
| Immunosuppressionh | 78 (7.5) | 69 (6.4)d | 111 (11.9)d | 98 (9.1) | 81 (8.0) | 96 (7.5) | 37 (3.8)d | 55 (9.1) | 59 (13.6)d | 69 (8.6) | 753 (8.2) |
| Emphysema or COPD | 88 (8.4) | 79 (7.4) | 111 (11.9)d | 73 (6.8) | 88 (8.7) | 84 (6.6)d | 73 (7.5) | 52 (8.6) | 33 (7.6) | 73 (9.1) | 754 (8.1) |
| Renal failure/dialysis | 88 (8.4)d | 66 (6.1) | 61 (6.5) | 94 (8.7)d | 64 (6.3) | 96 (7.5) | 62 (6.4) | 56 (9.2)d | 15 (3.5)d | 65 (8.1) | 667 (7.2) |
| Injection drug use | 161 (15.4)d | 39 (3.6) | 40 (4.3) | 16 (1.5)d | 142 (14.1)d | 10 (0.8)d | 64 (6.6)d | 13 (2.1)d | 31 (7.1)d | 18 (2.3)d | 534 (5.8) |
| Chronic skin breakdowni | 71 (13.3)d | 6 (1.2)d | 127 (25.7)d | 59 (10.3) | 75 (17.1)d | 39 (5.5)d | 26 (4.9)d | 27 (8.4) | 49 (22.4)d | 20 (4.4)d | 499 (10.1) |
| No underlying illness | 245 (23.5) | 372 (34.6)d | 223 (23.9) | 280 (26.1) | 167 (16.5)d | 382 (29.9)d | 222 (22.8) | 157 (25.9) | 95 (21.9) | 245 (30.6)d | 2388 (25.9) |
| >1 Underlying illnessj | 534 (51.2)d | 395 (36.7)d | 468 (50.1)d | 471 (43.8) | 593 (58.7)d | 465 (36.4)d | 449 (46.1) | 253 (41.7) | 226 (52.1)d | 331 (41.4)d | 4185 (45.3) |
Abbreviations: ABCs, Active Bacterial Core Surveillance; CA, California; CO, Colorado; COPD, chronic obstructive pulmonary disease; CT, Connecticut; GA, Georgia; MD, Maryland; MN, Minnesota; NM, New Mexico; NY, New York; OR, Oregon; TN, Tennessee.
Data represent No. (%) of underlying conditions, unless otherwise indicated.
Some patients had >1 underlying condition. The underlying condition was unknown for 325 case patients (3.4%). Conditions that totaled <5% of cases are not presented here and include cerebrovascular accident (366 cases; 4.0%), human immunodeficiency virus infection/AIDS (218 cases; 2.4%), and cirrhosis/liver failure (326 cases; 3.5%).
Tennessee data are from 11 counties for 2005–2009 and 20 counties for 2010–2012.
P < .05 (variation across sites when each site was compared with the mean).
Includes burns, varicella, blunt or penetrating trauma, and surgical wounds.
Includes heart failure or atherosclerotic cardiovascular disease.
Includes leukemia, myeloma, Hodgkin disease, or other cancers.
Resulting from immunoglobulin deficiency, treatment of systemic lupus erythematosus, nephrotic syndrome, organ or bone marrow transplantation, sickle cell disease, asplenia, or receipt of immunosuppressive therapy.
The chronic skin condition variable was added in 2009 and includes the presence of a current chronic dermatologic condition in which the integrity of the skin is compromised, such as psoriasis, eczema, decubitus ulcer, or other chronic ulcers. Numerators are divided by state-specific denominators for cases with known underlying conditions (CA, n = 534; CO, n = 520; CT, n = 494; GA, n = 575; MD, n = 439; MN, n = 707; NM, n = 531; NY, n = 320; OR, n = 219; TN, n = 456; total, n = 4795).
Data represent No. (%) of case patients with >1 underlying condition.